论文部分内容阅读
目的:探讨黄芪注射液联合红霉素治疗小儿支原体肺炎的临床效果及其安全性。方法:将2009年5月至2012年5月惠州市中心人民医院收治的270例支原体肺炎患儿随机分成3组:阿奇霉素组、红霉素组和联合组(黄芪注射液联用红霉素),每组90例。比较3组临床疗效、主要临床症状缓解消失时间、住院时间及不良反应发生的情况。结果:联合组痊愈率(77.8%)、总有效率(95.6%)高于红霉素组和阿奇霉素组的44.4%、82.2%和64.4%、92.2%(P<0.05):联合组症状体征缓解消失时间及住院时间短于红霉素组和阿奇霉素组(P<0.05):联合组不良反应率发生率最低(3.3%),其次为阿奇霉素组(11.1%),红霉素组最高(27.8%)。结论:黄芪注射液联合红霉素治疗小儿支原体肺炎疗效肯定,可缩短病程,减少不良反应的发生率。
Objective: To investigate the clinical effects and safety of astragalus injection combined with erythromycin in the treatment of children with mycoplasma pneumonia. Methods: From May 2009 to May 2012, 270 children with mycoplasma pneumonia admitted from Huizhou Central People’s Hospital were randomly divided into three groups: azithromycin group, erythromycin group and combination group (astragalus injection combined with erythromycin) , 90 cases in each group. The clinical efficacy, the disappearance of main clinical symptoms, the length of hospital stay and the occurrence of adverse reactions were compared between the three groups. Results: The cure rate (77.8%) and total effective rate (95.6%) in the combined group were higher than that in the erythromycin and azithromycin groups (44.4%, 82.2% and 64.4%, 92.2% The time of disappearance and hospital stay were shorter than that of erythromycin group and azithromycin group (P <0.05). The incidence of adverse reactions in combination group was the lowest (3.3%), followed by azithromycin group (11.1%) and erythromycin group (27.8% ). Conclusion: Astragalus injection combined with erythromycin treatment of children with mycoplasma pneumonia positive effect, can shorten the course of the disease and reduce the incidence of adverse reactions.